Get Premium to unlock powerful stock data
NAS:CLRB (USA)   Healthcare » Biotechnology
Cellectar Biosciences Inc logo

Cellectar Biosciences Inc $ 0.92 0.0061 (0.67%)

Volume:
294,349
Avg Vol (1m):
523,330
Market Cap $:
56.04 Mil
Enterprise Value $:
18.26 Mil
PE Ratio:
At Loss
PB Ratio:
1.43
Warning! GuruFocus has detected 1 Severe warning sign with CLRB. Click here to check it out.
Also Trade In: Germany
EMBED
5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Cellectar Biosciences Inc () from 2005 to Oct 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Cellectar Biosciences stock (CLRB) PE ratio as of Oct 17 2021 is 0. More Details

Cellectar Biosciences PE Ratio (TTM) Chart

EMBED

Cellectar Biosciences PE Ratio (TTM) Historical Data

Total 1217
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Cellectar Biosciences PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-10-17At Loss 2021-08-16At Loss
2021-10-15At Loss 2021-08-13At Loss
2021-10-14At Loss 2021-08-12At Loss
2021-10-13At Loss 2021-08-11At Loss
2021-10-12At Loss 2021-08-10At Loss
2021-10-11At Loss 2021-08-09At Loss
2021-10-08At Loss 2021-08-06At Loss
2021-10-07At Loss 2021-08-05At Loss
2021-10-06At Loss 2021-08-04At Loss
2021-10-05At Loss 2021-08-03At Loss
2021-10-04At Loss 2021-08-02At Loss
2021-10-01At Loss 2021-07-30At Loss
2021-09-30At Loss 2021-07-29At Loss
2021-09-29At Loss 2021-07-28At Loss
2021-09-28At Loss 2021-07-27At Loss
2021-09-27At Loss 2021-07-26At Loss
2021-09-24At Loss 2021-07-23At Loss
2021-09-23At Loss 2021-07-22At Loss
2021-09-22At Loss 2021-07-21At Loss
2021-09-21At Loss 2021-07-20At Loss
2021-09-20At Loss 2021-07-19At Loss
2021-09-17At Loss 2021-07-16At Loss
2021-09-16At Loss 2021-07-15At Loss
2021-09-15At Loss 2021-07-14At Loss
2021-09-14At Loss 2021-07-13At Loss
2021-09-13At Loss 2021-07-12At Loss
2021-09-10At Loss 2021-07-09At Loss
2021-09-09At Loss 2021-07-08At Loss
2021-09-08At Loss 2021-07-07At Loss
2021-09-07At Loss 2021-07-06At Loss
2021-09-06At Loss 2021-07-05At Loss
2021-09-03At Loss 2021-07-02At Loss
2021-09-02At Loss 2021-07-01At Loss
2021-09-01At Loss 2021-06-30At Loss
2021-08-31At Loss 2021-06-29At Loss
2021-08-30At Loss 2021-06-28At Loss
2021-08-27At Loss 2021-06-25At Loss
2021-08-26At Loss 2021-06-24At Loss
2021-08-25At Loss 2021-06-23At Loss
2021-08-24At Loss 2021-06-22At Loss
2021-08-23At Loss 2021-06-21At Loss
2021-08-20At Loss 2021-06-18At Loss
2021-08-19At Loss 2021-06-17At Loss
2021-08-18At Loss 2021-06-16At Loss
2021-08-17At Loss 2021-06-15At Loss

Cellectar Biosciences PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Cellectar Biosciences Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Traded in other countries / regions
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Website
http://www.cellectar.com
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.